NOW AVAILABLE

MANY MIGRAINE NEEDS

ONE SIMPLE SOLUTION

Nurtec® 75mg
oral lyophilisate
(rimegepant)

NURTEC—the first and only medicine to **TREAT** and **PREVENT** migraine attacks

NURTEC is indicated for the [1]:
- Acute treatment of migraine with or without aura in adults;
- Preventive treatment of episodic migraine in adults who have at least 4 migraine attacks per month.

TREAT

In a clinical study, acute treatment with NURTEC led to:

2X Nearly twice as many patients achieving pain freedom at 2 hours vs placebo[1*]

60 MIN

Significant improvement in percentage of patients with **pain relief at 60 minutes**, sustained for **up to 48 hours** compared to placebo[2†]

86% of patients on NURTEC **did not require rescue medication** in the first 24 hours vs 71% with placebo[2]

PREVENT

In a clinical study, preventive treatment with NURTEC[‡] led to:

48h

Significant reduction in monthly mean migraine days (MMDs) at Weeks 9-12 vs placebo[3§]

Significant improvement in percentage of patients achieving ≥50% reduction in MMDs at Weeks 9-12 vs placebo[3‖]

Long-term efficacy in preventing MMDs[1¶]

NURTEC has an **adverse event profile similar to placebo** and **simple dosing**[2]

SAFETY

No serious adverse events were reported in the acute study while less than 1% of subjects reported serious adverse events in the prevention study.[2,3] The most common adverse reaction was nausea.[1]

SIMPLE DOSING

Treat and prevent migraine attacks with one NURTEC 75 mg, an orally dissolving tablet.[1]
- **Acute treatment:** taken as needed up to once daily[1]
- **Preventive treatment:** taken every other day[1]

The maximum dose per day is 75 mg rimegepant.[1]

*21.2% of patients taking NURTEC achieved pain freedom at 2 hours vs 10.9% on placebo.[1]
†36.8% of patients taking NURTEC had pain relief at 60 minutes vs 31.2% on placebo, and 42.2% of patients taking NURTEC had pain relief sustained up to 48 hours vs 25.2% with placebo.[2]
‡This study evaluated a rimegepant 75 mg tablet formulation bioequivalent to NURTEC.[1]
§MMDs for patients taking NURTEC reduced by 4.3 vs a reduction of 3.5 MMDs with placebo.[3]
‖49.1% of patients taking NURTEC achieved ≥50% reduction in MMDs vs 41.5% with placebo.[3]
¶Efficacy was sustained during the 12-month open-label extension period. The overall mean reduction from baseline in MMDs averaged over the 16-month treatment period was 6.2 days.[1]

Want additional information on NURTEC?

Learn more >

Pfizer

Scan the QR code or type URL in your browser to find the Full Prescribing Information

www.pfi.sr/Ujh

The QR code/URL links to the latest Prescribing Information approved by the Department of Health in Hong Kong and may not be effective and the same as presented in the actual product package.

FULL PRESCRIBING INFORMATION IS AVAILABLE UPON REQUEST.

For Healthcare Professionals only.

References:

1. NURTEC (rimegepant) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version November 2022 **2.** Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. *Lancet*. 2019;394(10200):737-745. **3.** Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. *Lancet*. 2021;397(10268):51-60.

Pfizer Corporation Hong Kong Limited
18/F, Kerry Centre, 683 King's Road, Quarry Bay, Hong Kong.
Tel: (852) 2811 9711 Fax: (852) 2579 0599
Website: www.pfizer.com.hk

Nurtec® 75mg
oral lyophilisate
(rimegepant)

Pfizer